(4-氨基-3-溴苯基)乙腈 | 882855-96-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (4-氨基-3-溴苯基)乙腈
• 英文名称: 2-(4-amino-3-bromophenyl)acetonitrile
• 英文别名: (4-Amino-3-bromophenyl)acetonitrile
• CAS: 882855-96-1
• 化学式: C₈H₇BrN₂
• 分子量: 211.061
• InChiKey: JWDNUJFNVCIOTJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2926909090
• 危险性防范说明：
  P233,P260,P261,P264,P270,P271,P280,P301+P312,P302+P352,P304,P304+P340,P305+P351+P338,P312,P321,P322,P330,P332+P313,P337+P313,P340,P362,P363,P403,P403+P233,P405,P501
• 危险性描述：
  H302,H312,H315,H319,H332,H335
• 储存条件：
  存储条件：2-8°C，避光，惰性气体

反应信息

• 作为反应物：
  描述：

  (4-氨基-3-溴苯基)乙腈 在 四(三苯基膦)钯 、 三甲基甲硅烷基锡 、 sodium carbonate 作用下， 以 1,4-二氧六环 、 水 、 甲苯 为溶剂， 反应 5.0h， 生成 4-cyano-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazole-2-carboxylic acid [2-(4,4-dimethyl-cyclohex-1-enyl)-4-(1H-tetrazol-5-ylmethyl)-phenyl]-amide
  参考文献：
  名称：

  Enhancement of kinase selectivity in a potent class of arylamide FMS inhibitors

  摘要：

  Structure-activity relationship (SAR) studies on a highly potent series of arylamide FMS inhibitors were carried out with the aim of improving FMS kinase selectivity, particularly over KIT. Potent compound 17r (FMS IC50 0.7 nM, FMS cell IC50 6.1 nM) was discovered that had good PK properties and a greater than fivefold improvement in selectivity for FMS over KIT kinase in a cellular assay relative to the previously reported clinical candidate 4. This improved selectivity was manifested in vivo by no observed decrease in circulating reticulocytes, a measure of bone safety, at the highest studied dose. Compound 17r was highly active in a mouse pharmacodynamic model and demonstrated disease-modifying effects in a dose-dependent manner in a strep cell wall-induced arthritis model of rheumatoid arthritis in rats. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.09.061
• 作为产物：
  描述：

  对氨基苯乙腈 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 乙腈 为溶剂， 以91.4 %的产率得到(4-氨基-3-溴苯基)乙腈
  参考文献：
  名称：

  [EN] N-SUBSTITUTED PHENYLSULFONAMIDE COMPOUND AND USE THEREOF
  [FR] COMPOSÉ DE PHÉNYLSULFONAMIDE N-SUBSTITUÉ ET SON UTILISATION
  [ZH] N-取代苯基磺酰胺类化合物及其用途

  摘要：

  本发明涉及N-取代苯基磺酰胺类化合物及其用途。具体地，本发明提供一种如式I化合物，或其光学异构体，或其外消旋体、或其药学上可接受的盐。本发明所述的化合物对瞬时受体电位通道蛋白具有优异的抑制作用，并对瞬时受体电位通道蛋白相关的疾病如炎症性肠病、肠易激综合征、疼痛和炎症等具有优异的治疗作用。

  公开号：

  WO2022262657A1

文献信息

• [EN] TETRACYCLIC BROMODOMAIN INHIBITORS<br/>[FR] INHIBITEURS DE BROMODOMAINES TÉTRACYCLIQUES
  申请人：ABBVIE INC

  公开号：WO2014139324A1

  公开（公告）日：2014-09-18

  The present invention provides for compounds of formula (I) wherein R1, R2, R6, Y1, Υ2, Υ3, A1, A2, A3 and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

  本发明提供了具有以下式（I）的化合物，其中R1、R2、R6、Y1、Y2、Y3、A1、A2、A3和A4具有规范中定义的任何值，以及其药学上可接受的盐，这些化合物可用作治疗疾病和病况的药剂，包括炎症性疾病、癌症和艾滋病的药剂。还提供了包含一个或多个具有式（I）的化合物的药物组合物。
• [EN] IMIDAZO [4, 5 -C] PYRIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES<br/>[FR] DÉRIVÉS D'IMIDAZO [4, 5-C] PYRIDINE UTILES POUR LE TRAITEMENT DE MALADIES DÉGÉNÉRATIVES ET INFLAMMATOIRES
  申请人：GALAPAGOS NV

  公开号：WO2013117649A1

  公开（公告）日：2013-08-15

  Novel imidazolopyridines according to Formula I, able to inhibit JAK are disclosed, wherein R1 and Cy are as disclosed herein. These compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic or inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons.

  根据公式I揭示了能够抑制JAK的新型咪唑吡啶类化合物，其中R1和Cy如本文所述。这些化合物可以制备为药物组合物，并可用于预防和治疗哺乳动物包括人类的各种疾病，包括但不限于过敏或炎症性疾病、自身免疫疾病、增生性疾病、移植排斥、涉及软骨周转障碍的疾病、先天软骨畸形以及与IL6或干扰素过度分泌相关的疾病。
• Cyanomethylation of the Benzene Rings and Pyridine Rings via Direct Oxidative Cross-Dehydrogenative Coupling with Acetonitrile
  作者：Hua Yao、Xiaoyang Zhong、Bingqing Wang、Sen Lin、Zhaohua Yan

  DOI：10.1021/acs.orglett.2c00498

  日期：2022.3.18

  and efficient approach for the amine-directed dehydrogenative C(sp2)–C(sp3) coupling of arylamines with acetonitrile was reported by using FeCl2 as the catalyst. Substituted anilines, aminopyridines, naphthylamines, and some nitrogen-containing heterocyclic arylamines react with inactive acetonitrile to form the corresponding arylacetonitriles in moderate to good yields. This protocol features nontoxic

  报道了一种使用 FeCl 2作为催化剂的芳胺与乙腈的胺定向脱氢 C(sp 2 )-C(sp 3 ) 偶联的新型有效方法。取代的苯胺、氨基吡啶、萘胺和一些含氮杂环芳基胺与惰性乙腈反应生成相应的芳基乙腈，产率适中至高。该协议具有无毒的铁催化、高效的原子经济性、非预功能化的起始材料、良好的区域选择性以及官能团和芳环的良好相容性，为芳基乙腈提供了一种新颖、直接和绿色的方法。
• c-fms kinase inhibitors
  申请人：Player R. Mark

  公开号：US20060258666A1

  公开（公告）日：2006-11-16

  The invention is directed to compounds of Formula II: wherein A, R 1 , R 2 , R 3 , R 4 , X, Y and W are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.

  本发明涉及公式II的化合物： 其中A、R1、R2、R3、R4、X、Y和W在说明书中有所阐述，以及其溶剂化物、水合物、互变异构体或药学上可接受的盐，其可抑制蛋白酪氨酸激酶，特别是c-fms激酶。
• TETRACYCLIC BROMODOMAIN INHIBITORS
  申请人：ABBVIE INC.

  公开号：US20160039821A1

  公开（公告）日：2016-02-11

  The present invention provides for compounds of formula (I) wherein R 1 , R 2 , R 6 , Y 1 , Y 2 , Y 3 , A 1 , A 2 , A 3 and A 4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

  本发明提供了公式（I）的化合物，其中R1，R2，R6，Y1，Y2，Y3，A1，A2，A3和A4具有规范中定义的任何值，以及其药学上可接受的盐，可用作治疗疾病和病况的药物，包括炎症性疾病，癌症和艾滋病。还提供了包含一个或多个公式（I）化合物的制药组合物。